A recent study indicates that people who come off popular slimming jabs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who stop conventional diet and exercise plans.
Published data in a prominent medical journal points out that while overweight people often shed a large proportion of their body weight while undergoing treatment, the mass is regained at an estimated rate of nearly a kilo each month after stopping.
"People buying such treatments must be informed of the potential of quick rebound weight gain when the therapy ends," warns expert Dr. Susan Jebb.
Such speed of regain means a reversion to pre-treatment mass within about one and a half years.
Analyzing Approaches
The analysis, which examined dozens of studies involving over 9,000 of participants, contrasted the outcomes of the injectable medications with other pills.
Researchers note that individuals who shed pounds through dieting usually experience a slower weight regain—approximately 0.1 kg a month—post-intervention.
Understanding the Rapid Regain
Doctors propose the way of the jabs is key to understanding the amplified regain.
These medications copy a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Long-term administration of GLP-1 concentrations far above than normal could lead to the body to generate a reduced amount of its endogenous GLP-1, and could lessen sensitivity to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' results in appetite is unsuppressed, making excessive eating far more likely."
A Lifelong Issue?
The NHS recommend the jabs for people with obesity-related health risks, accompanied by prescribed lifestyle changes.
A number of clinicians say that, due to the likelihood of weight regain, the treatment should be considered long-term.
This perspective is supported by drug manufacturers, who say that the findings "highlight the persistent character of excess weight," similar to managing diseases like hypertension.
Patient Testimonies
Users who have come off the jabs explain a intense return of cravings.
"It was like something that goes on and I was suddenly ravenous," recalled a patient.
This difficulty is exacerbated if users have not adopted sustainable lifestyle or habit changes during therapy.
Widespread Use
Figures suggest that millions of people in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Adoption is more common among women compared to men.
- The 40s and 50s demographic shows the highest level of interest.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, researchers caution that while these medications are powerful agents for weight loss, they are not a magic solution and lasting health benefits likely depends on combined behavioural support.
